Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that selective vitamin D receptor
activation reduces left ventricular hypertrophy and ameliorates inflammation and
atherosclerosis in stage 3 -5 chronic kidney disease.